There are currently 218 clinical trials in Santa Monica, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Citruslabs, Clinical Science Institute, Sarcoma Oncology Center and John Wayne Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
NCT06125197
Recruiting
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California
Conditions: Lung Cancer
Register for Updates
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Recruiting
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: UCLA, Santa Monica, California
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Register for Updates
Work Time Schedule Changes for Nurse Managers
NCT06406478
Recruiting
The goal of this clinical trial is to explore how working a 4-day schedule impacts nurse manager wellbeing and job performance. The main questions it aims to answer are: * Do those working 4-days have improved wellbeing with reduced levels of burnout and work/family conflict when compared to those in the control group? * Do levels of sleep, heart rate variability, and physical activity significantly differ between those working the 4-day schedule change and those in the control group? * Are nur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: UCLA Health, Santa Monica, Santa Monica, California
Conditions: Work-Related Condition
Register for Updates
Starting Technology in At Risk Type 1 Diabetes Study
NCT06453928
Recruiting
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c\>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: UCLA, Santa Monica, California
Conditions: Diabetes Mellitus, Type 1
Register for Updates
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
NCT04673942
Recruiting
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Providence Saint John's Health Center, Santa Monica, California
Conditions: Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
Register for Updates
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613
Recruiting
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Providence St. Johns Health Center, Santa Monica, California
Conditions: Breast Cancer
Register for Updates
Genicular Artery Embolization Vs Observation for Symptomatic Knee Osteoarthritis
NCT04682652
Recruiting
The purpose of this clinical trial is to determine whether genicular artery embolization (GAE) is an effective way to treat knee pain from osteoarthritis. Pain from arthritis is often due to underlying inflammation in the joint. The inflammation is associated with increased abnormal blood flow going to the specific area of pain. If the investigator can reduce the blood flow, the inflammation can be reduced and the pain can be controlled. The GAE procedure is an experimental procedure to decreas... Read More
Gender:
ALL
Ages:
Between 40 years and 79 years
Trial Updated:
09/28/2024
Locations: UCLA Santa Monica Hospital, Santa Monica, California
Conditions: Knee Osteoarthritis, Degenerative Joint Disease of Knee
Register for Updates
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
NCT04875702
Recruiting
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/26/2024
Locations: UCLA Health, Santa Monica, California
Conditions: Gout
Register for Updates
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT06471673
Recruiting
This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If onc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast
Register for Updates
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: University of California Los Angeles (UCLA), Santa Monica, California
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868
Recruiting
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2024
Locations: Sarcoma Oncology Research Center, Santa Monica, California
Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
Register for Updates
Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision
NCT06107881
Recruiting
One goal of this research is to conduct a non-inferiority trial of telerehabilitation versus in-office care to provide follow-up training to individuals with low vision to enhance their quality of life by using magnification devices and/or visual assistive mobile apps for important daily activities, such as reading and/or other valued tasks. This is a high priority given the increasing prevalence of low vision, paucity of low vision rehabilitation providers, and barriers related to access to car... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: See What You Miss Optometry, Santa Monica, California
Conditions: Low Vision, Low Vision Aids
Register for Updates